Table 4:
Change in Depression Scores on Alternative Depression Scales at Final Follow-Up
| Scale Test | Author, Year | No. PGx/TAU | Mean at Follow-Up (SD) or Mean Δ From baseline (SD) | % Decrease From Baseline | P Valuea | ||
|---|---|---|---|---|---|---|---|
| PGx | TAU | PGx | TAU | ||||
| QIDS-C16 | |||||||
| GeneSight | Greden et al, 201957 | 621/678 | NR | NR | 35.1 | 32.9 | .19 |
| Winner et al, 201365 | 25/24 | NR | NR | 27.6 | 22.1 | NS | |
| Hall-Flavin et al, 201355 | 72/93 | 9.65b (NE) | 11.24b (NE) | 44.8 | 26.4 | < .0001c | |
| Hall-Flavin et al, 201256 | 22/22 | 10.92b (NR) | 13.91b (NR) | 31.2 | 7.2 | .002d | |
| Genecept | Perlis et al, 202061 | 146/150 | Δ –6.04 (5.4) | Δ –6.45 (5.1) | NR | NR | MD: 0.39 |
| 9-Item Patient Health Questionnaire | |||||||
| GeneSight | Greden et al, 201957 | 621/678 | NR | NR | 34.1 | 29.3 | .04 |
| Winner et al, 201365 | 25/24 | NR | NR | 35.4 | 21.3 | .18 | |
| Hall-Flavin et al, 201355 | 72/93 | 10.07b (NE) | 11.61b (NE) | 40.1 | 19.5 | < .0001e | |
| Neuropharmagen | Han et al, 201859,60 | 52/48 | Δ –13.6 (6.8) | Δ –9.8 (7.8) | NR | NR | .05f |
| HAM-D6 | |||||||
| GeneSight | Dunlop et al, 201966 (Greden et al, 201957) |
621/677 | NR | NR | 28.3 | 23.9 | .023 |
| Clinical Global Impression Scale-Severity | |||||||
| Neuropharmagen | Perez et al, 201762 | CR: 144/143 PR: unclear |
Δ –1.14 (1.13) Δ –1.09 (1.37) |
Δ –0.87 (1.13) Δ –0.87 (1.38) |
NR NR |
NR NR |
MD: .04 MD: .18 |
| Han et al, 201859,60 | CR: 52/48 | Δ –3.3 (1.4) | Δ –2.3 (1.8) | NR | NR | MD: .02f | |
| Genecept | Perlis et al, 202061 | 146/150 | Δ –1.74 (1.26) | Δ –1.65 (1.21) | NR | NR | MD: .56 |
Abbreviations: Δ, change from baseline to follow-up; CR, clinician-rated; HAM-D6, 6-item Hamilton Depression Rating Scale; ITT, intent-to-treat; MD, mean difference; NE, not estimated; NR, not reported; NS, not significant; PGx, pharmacogenomic-guided treatment selection; PR, patient rated; QIDS-C16, 16-item Quick Inventory of Depressive Symptomatology; TAU, treatment as usual; SD, standard deviation.
P values reflect differences in percent decrease from baseline to follow-up between PGx and TAU groups unless otherwise noted as MDs. Values are presented as reported in original article.
Estimated using WebPlotDigitizer software based on graphs in the publication. Standard errors and deviations were not extracted from figures.
Result based on endpoint analysis. Repeated measures analysis P < .001.
Result based on endpoint analysis. Repeated measures analysis P = .05.
Result based on endpoint analysis. Repeated measures analysis P = .002.
Mean differences and CIs not calculated from reported data, as reported P values were adjusted by authors.